Journal of Clinical Oncology · 2008 · 25 citations · 0 references
MedicineBiomedical SciencesOncologyChemotherapyClinical Radiation OncologyRadiobiologyBrain TumorsGlioblastomaGlioma RadiotherapyRadiation TherapyHyperthermiaRadiofrequency TreatmentTemozolomide Therapy
2047 Background: In spite of many new approaches the treatment of malignant gliomas is still disappointing. Concomitant radiotherapy with temozolomide could improve in a RCT median survival of pts with glioblastoma multiforme from 12.1 to 14.6 months (EORTC 26981- 22981; NCIC,3; ASCO 2004). About 20% of pts with gliomas benefit from therapy depending on genomic mutations. Deep hyperthermia with low radiofrequency capacitive coupled electrodes (LRF-DHT) at 13.56 MHz is feasible in treating pts with brain tumors (Hager ED et al., ASCO 2003,#470). 4/5 of the effective LRF-energy can induce selectively apoptosis in cancer cells instead of heat. Heat alone would be contraindicated for the treatment of tumors in the brain. Therefore, electro-hyperthermia (EHT) is also referred to this technique. Methods: N=179 pts with highly- malignant gliomas (WHO grade III/IV at recurrence or progression) where treated with LRF-DHT after recurrence and/or progression after first-line therapy of the disease after surgery, radiotherapy and/or chemotherapy. N= 53 pts in the astrocytoma WHO grade III group and N=126 pts in the WHO grade IV group (glioblastoma multiforme), KI >50%, where analyzed in an intention-to-treat observational study. Enrollment time was from 02/2000 to 04/2007. Results: Complete data where collected from all pts and considered for evaluation if at least 1 cycle of LRF-DHT could be performed. The median overall survival times (MST) are listed in table 1. Longstanding complete and partial remissions could be achieved after recurrence in both groups. Conclusions: LRF-DHT is feasible in treating pts with highly malignant gliomas without any severe side effects. Hyperthermia with capacitive coupled electrodes may increase overall median survival time (MST) by about 6 months after recurrence and/or progression after first-line therapy. Quality of life and survival could be improved by this method. Further trials are urgently warranted. MST of patients with WHO grade III and IV gliomas (Kaplan-Meier Estimation) MST from Grade III; N =: 53 pts months±se [95%CI] Grade IV; N = 126 pts months±se [95%CI] 1st Diagnosis of Disease 37.0±3.7 [29.8; 44.2] 19.0±1.6 [15.9; 22.1] 1st LRF- Hyperthermia 10.0±1.9 [6.3; 13.7] 7.0±0.8 [5.4; 8.6] Censored N (%) 25 (19.8%) 14 (26.4%) No significant financial relationships to disclose.